INTRODUCTION
• Chemotherapy-induced nausea and vomiting (CINV) is a common and potentially debilitating side effect of cancer treatment.
• CINV is characterized by an acute phase (<24 hours post chemotherapy) mediated by peripheral 5-hydroxytryptamine type 3 (5-HT 3 ) receptors and a delayed phase (24- recommend a regimen of dexamethasone, a 5-HT 3 receptor antagonist (RA), and an NK-1 RA for patients administered highly emetogenic chemotherapy (HEC) and select patients administered moderately emetogenic chemotherapy (MEC).
• Rolapitant (VARUBI ® ), a long-acting NK-1 RA, was approved in oral formulation by the US Food and Drug Administration in September 2015 in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic chemotherapy, including but not limited to HEC. 
METHODS
• Searches were conducted in the MEDLINE, Embase, and Cochrane library electronic databases.
• Hand searches were performed for 2010-2015 congress proceedings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), ASCO, the American Society of Hematology (ASH), ESMO, and MASCC.
• Additional data sources were ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, FDA.gov, and the EudraCT website.
• Publications were screened using the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Figure 2 ). • Publications were included if they reported primary data from phase 2 or 3 randomized controlled trials (RCTs) of NK-1 RAs (aprepitant, fosaprepitant, netupitant, or rolapitant) for the treatment of CINV.
Figure 2. PRISMA Flow Diagram
• Publication dates ranged from 1999 to 2015 (Figure 3) .
• The quality of the identified evidence was assessed using a checklist recommended by the National Institute for Health and Care Excellence for evaluating RCTs. 
RESULTS
• Of 1069 articles identified in the electronic databases and 9 abstracts identified by hand-searching, 29 publications (22 articles and 7 conference abstracts) on 29 RCTs met the inclusion criteria (Figures 2  and 4A ).
• Across all RCTs, a total of 15,383 patients were randomized; the sample size of individual RCTs ranged from 53 to 2322 patients.
• RCTs evaluated aprepitant (n=17), fosaprepitant (n=5), the netupitant/palonosetron (NEPA) fixed-dose combination (n=3), and rolapitant (n=4).
• In all, 23 studies compared NK-1 RAs with antiemetic therapy (5-HT 3 RA plus dexamethasone), 3 studies compared NK-1 RAs with olanzapine, and 3 studies were head-to-head comparisons of NK-1 RAs (Figure 4B ).
• Nineteen RCTs evaluated patients administered HEC (all cisplatin-based), 8 RCTs evaluated patients administered MEC, and 2 RCTs evaluated patients administered either HEC or MEC ( Figure 4C ). • None of the RCTs identified directly compared rolapitant with other NK-1 RAs.
• A total of 18 RCTs were considered potentially relevant for an indirect comparison of rolapitant with other NK-1 RAs via the use of a common comparator arm, ie, therapy with a 5-HT 3 RA and dexamethasone ( Table 1 ).
-Endpoints reported for the acute phase (AP; ≤24 hours), delayed phase (DP; >24-120 hours), and overall phase (OP; 0-120 hours) of CINV in each RCT are shown in Table 1 . 
CONCLUSIONS
• Our systematic review identified RCTs evaluating NK-1 RAs for CINV prevention in patients undergoing treatment with HEC or MEC.
• The absence of head-to-head trials evaluating rolapitant with other NK-1 RAs precludes direct comparisons of these agents.
• A network meta-analysis to indirectly compare efficacy and safety of rolapitant with other NK-1 RAs is ongoing. 
